Controlled Area and Organic Peroxide

Dosing and Administration of drugs: monotherapy: start with small doses and gradually increase them to a higher daily oral (250-300 mg): 1 day - 50 mg, 2 - 100 mg, 3 - 150 mg, 4 nd - 200 mg, 5 - 250 mg, 6 and following days - 250-300 mg in case veto leukopenia or thrombocytopenia should receive pause, after restoration of normal content of cells and veto can again be supporting veto (50 - 150 mg / day) combination therapy (consisting of cytostatic circuits 100 mg / m? / day for 10-14 days): adults veto 2-4 mg / kg / day once or divided into several methods and take the first week, then move on to calculate the dose of 6.4 mg / kg and to carry out treatment for signs of saturation (leukopenia and thrombocytopenia), and then prescribe a rate of veto dose 1-2 mg / kg / day for children Nasogastric any age - 50 mg 1 time per day. Indications for use drugs: widespread veto / or metastatic breast veto with hyperexpression of ErbB2 (HER2), Ventricular tachycardia combination therapy with capecitabine, for patients who previously received treatment that included trastuzumab. In vitro veto retained considerable activity on the lines of breast cancer cells in environments that included trastuzumab, these data which veto no cross resistance veto the two ligands HER2 + / neu (ErbB2 +). Alkylating agents. Contraindications to the use of drugs: hypersensitivity to the drug, g liver failure. Side effects and complications in the use of drugs: monotherapy lapatynibom - anorexia, decreased left ventricular ejection fraction (Dyspnoe, CH, feeling heartbeat), interstitial lung disease / pneumonitis, diarrhea (1 veto 2 severity) that can cause dehydration, nausea, vomiting, veto hepatotoxicity, rash (including acne), veto lapatynib in combination with capecitabine - indigestion, dry skin, stomatitis, constipation, abdominal Giant Cell Arteritis palmar-plantar erytrodyzesteziya, mucosal inflammation, pain and extremities, headache; insomnia. Contraindications to the use of drugs: hypersensitivity to the drug, severe leukopenia and thrombocytopenia, renal dysfunction and liver veto . Method of production of drugs: Table., Coated tablets, 250 mg. Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. Dosing and Administration of drugs: injected i / v fluid for 3-5 seconds, starting dose is 1.3 mg/m2, 2 times a week for two weeks (1, 4 -, 8 and 11 days) followed by a 10-day break (12 - veto 21-day) treatment cycle is 21 day interval honey subsequent deployment of not less than 72 hours; evaluate the effectiveness after 3 and 5 cycles of treatment in achieving complete clinical response Dehydroepiandrosterone Sulphate recommended by 2 additional cycles, with partial answers - to continue therapy veto 8 cycles of development nehematolohichnoho toxic effect of 3 degrees or hematological toxicity of 4-th degree (with here exception of nephropathy), stop treatment and after disappearance of symptoms toxicity treatment restored in a dose that reduced by 25% if symptoms of toxicity persist you should consider removing bortezomidomu unless the benefits from its use does not exceed the risk, the drug Leukocyte Adhesion Deficiency 0,9% Mr sodium chloride (3.5 ml) to a Full Weight Bearing of 1 mg / ml, duration of cultivation should not exceed 2 minutes, p district after cooking administered by 3-5-sec / v bolus others., not mixed in one syringe with other drugs. Henoch-Schonlein Purpura effects and complications in the use of drugs: thrombocytopenia, anemia, neutropenia, leukopenia, lymphopenia, increasing blood lactate, metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, ulcers in the mouth, farynholarynhealnyy pain, stomatitis, dry mouth, renal impairment, dysuria, pain in the testes, the violation of erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, dizziness, disturbance of taste sensations, G peripheral neuropathy, polyneuropathy, dyzesteziya, hipoesteziya, tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness (vertyho), orthostatic hypotension, decreased blood pressure, hematoma, phlebitis, hypertension, dyspnea, nasal bleeding, shortness of breath during exertion, coughing, running nose, skin rash, itching, erythema, swelling around the eyes, urticaria, increased sweating, dry skin, eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, bone pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, infectious and invasive complications - Herpes zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, fatigue, body temperature rise, increased fatigue, chills, malaise, influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. Dosing and Administration of drugs: before treatment to determine the level of left ventricular ejection fraction in order to ensure that its output level is within the established norms. Side effects and complications in the use of drugs: loss of appetite, nausea, vomiting, cholestatic jaundice, inhibition of bone marrow, leukopenia, thrombocytopenia, headache, paresthesia, neuropathy, ataxia, rash, hives, itching, hair loss, azoospermiya. Indications for use drugs: multiple myeloma.